AU2636600A - Method for the prevention or reduction of cardiovascular events associated with coronary intervention - Google Patents

Method for the prevention or reduction of cardiovascular events associated with coronary intervention Download PDF

Info

Publication number
AU2636600A
AU2636600A AU26366/00A AU2636600A AU2636600A AU 2636600 A AU2636600 A AU 2636600A AU 26366/00 A AU26366/00 A AU 26366/00A AU 2636600 A AU2636600 A AU 2636600A AU 2636600 A AU2636600 A AU 2636600A
Authority
AU
Australia
Prior art keywords
days
coronary intervention
treatment period
pharmaceutically acceptable
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26366/00A
Other languages
English (en)
Inventor
Jeffrey R. Granett
Neil H. Shusterman
David C. U'prichard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2636600A publication Critical patent/AU2636600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU26366/00A 1999-02-03 2000-02-02 Method for the prevention or reduction of cardiovascular events associated with coronary intervention Abandoned AU2636600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11846299P 1999-02-03 1999-02-03
US60118462 1999-02-03
PCT/US2000/002622 WO2000045811A1 (en) 1999-02-03 2000-02-02 Method for the prevention or reduction of cariovascular events associated with coronary intervention

Publications (1)

Publication Number Publication Date
AU2636600A true AU2636600A (en) 2000-08-25

Family

ID=22378750

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26366/00A Abandoned AU2636600A (en) 1999-02-03 2000-02-02 Method for the prevention or reduction of cardiovascular events associated with coronary intervention

Country Status (17)

Country Link
EP (1) EP1171116A4 (ko)
JP (1) JP2002536327A (ko)
KR (1) KR20010101934A (ko)
CN (1) CN1345237A (ko)
AU (1) AU2636600A (ko)
BR (1) BR0007921A (ko)
CA (1) CA2361581A1 (ko)
CO (1) CO5150206A1 (ko)
HK (1) HK1045104A1 (ko)
HU (1) HUP0200129A3 (ko)
IL (1) IL144721A0 (ko)
MX (1) MXPA01007835A (ko)
NO (1) NO20013788L (ko)
PL (1) PL351397A1 (ko)
TR (1) TR200102245T2 (ko)
WO (1) WO2000045811A1 (ko)
ZA (1) ZA200106353B (ko)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
AU6837096A (en) * 1995-09-07 1997-03-27 Kissei Pharmaceutical Co. Ltd. 2-acylaminobenzamide derivatives and preventive and remedy for diseases caused by the supermultiplication of vascular intimal cells
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
HK1045104A1 (zh) 2002-11-15
EP1171116A4 (en) 2004-11-17
EP1171116A1 (en) 2002-01-16
CA2361581A1 (en) 2000-08-10
NO20013788D0 (no) 2001-08-02
JP2002536327A (ja) 2002-10-29
TR200102245T2 (tr) 2002-05-21
BR0007921A (pt) 2002-09-10
HUP0200129A2 (hu) 2002-05-29
KR20010101934A (ko) 2001-11-15
CN1345237A (zh) 2002-04-17
HUP0200129A3 (en) 2003-06-30
MXPA01007835A (es) 2002-04-24
CO5150206A1 (es) 2002-04-29
WO2000045811A1 (en) 2000-08-10
IL144721A0 (en) 2002-06-30
ZA200106353B (en) 2002-08-02
NO20013788L (no) 2001-09-28
PL351397A1 (en) 2003-04-07

Similar Documents

Publication Publication Date Title
US5385935A (en) Method for the inhibition of restenosis associated with coronary intervention
TW389696B (en) Accelerated release composition containing bromocriptine
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
HUT71234A (en) Pharmaceutical compositions inhibiting smooth muscle cell proliferation and restinosis containing 2-phenyl-3-aroyl-benzotiophene- and 2-phenyl-3-aroyl-naphtalene derivatives and process for their preparation
KR19980064024A (ko) 약학 조성물
HU217833B (hu) Eljárás difenil-butil-piperazin-karboxamidokat tartalmazó, mértéktelen szerfogyasztásból eredő betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
WO2005084392A2 (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
JP3007992B2 (ja) （ｒ）−アムロジピンによる平滑筋細胞の遊走の抑制
AU2007234917B2 (en) Renin inhibitors for the treatment of hypertension
AU2636600A (en) Method for the prevention or reduction of cardiovascular events associated with coronary intervention
AU2978500A (en) Method for the prevention or reduction of cardiovascular events associated with coronary intervention
WO2001062241A1 (en) Method for the prevention or reduction of vascular access dysfunction
WO2001097798A1 (en) Method for the prevention or reduction of cardiovascular events associated with coronary intervention
JPH04338328A (ja) 血管形成阻害剤として有用なベンゾイルカルビノール及びそのエステル
KR100817932B1 (ko) 베르바민을 유효성분으로 포함하는 혈관 재협착 예방제
CA2465807A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU627277B2 (en) A method of treatment or prevention of post-ptca restenosis by post-ptca restenosis inhibitor
AU701287B2 (en) The pharmacological use of certain cystine derivatives
US20080139668A1 (en) Pharmaceutical composition for obovatol for the prevention and treatment of restenosis
JPH0788300B2 (ja) エピニンあるいはその製薬的に許容しうる塩を含む医薬組成物ならびに用途
US5354770A (en) Using imidazolyl tetrahydronaphthalene carboxylic acids to inhibit restenosis
KR100806541B1 (ko) 아세클로페낙을 함유하는 제어 방출성 제제
WO2002056941A2 (en) Method for the treatment of peripheral vascular disease
JPH02289515A (ja) Ｐｔｃａ後の再狭窄抑制剤

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTION TITLE TO READ METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH CORONARY INTERVENTION

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted